Members of the association Act Up hold signs in front of a stand of US pharmaceutical giant Gilead Sciences to denounce the high price of a new drug, Sofosbuvir, to treat Hepatitis C, on April 29, 2014 in Montpellier, southern France. In the United States, Gilead priced 730 euros per Sofosbuvir pill for a treatment which can last from 12 to 24 weeks. The World Health Organization estimates there are 184 million people infected with hepatitis C worldwide through sources such as transfusions, with the disease causing half a million deaths annually. Signs read ”Nepal, annual income 340 USD, price of Sofosbuvir 900-1 000 USD”.
AFP PHOTO / SYLVAIN THOMAS / AFP / SYLVAIN THOMAS